The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: Anti-bacterial thiazole derivatives.
However, not all innovations are equal and nor do they follow a constant upward trend. Instead, their evolution takes the form of an S-shaped curve that reflects their typical lifecycle from early emergence to accelerating adoption, before finally stabilising and reaching maturity.
Identifying where a particular innovation is on this journey, especially those that are in the emerging and accelerating stages, is essential for understanding their current level of adoption and the likely future trajectory and impact they will have.
110 innovations will shape the pharmaceutical industry
According to GlobalData’s Technology Foresights, which plots the S-curve for the pharmaceutical industry using innovation intensity models built on over 756,000 patents, there are 110 innovation areas that will shape the future of the industry.
Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin-1, which are now well established in the industry.
Innovation S-curve for the pharmaceutical industry
Anti-bacterial thiazole derivatives is a key innovation area in pharmaceuticals
Thiazoles are five membered aromatic heterocycles containing sulphur and nitrogen atoms. Thiazoles and its derivatives have broad applications in drug development. Thiazole derivatives exhibit significant antibacterial activity against various bacteria and pathogens.
GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 170+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of anti-bacterial thiazole derivatives.
Key players in anti-bacterial thiazole derivatives – a disruptive innovation in the pharmaceutical industry
‘Application diversity’ measures the number of different applications identified for each relevant patent and broadly splits companies into either ‘niche’ or ‘diversified’ innovators.
‘Geographic reach’ refers to the number of different countries each relevant patent is registered in and reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.
Patent volumes related to anti-bacterial thiazole derivatives
|Company||Total patents (2010 - 2021)||Premium intelligence on the world's largest companies|
|Wockhardt||353||Unlock company profile|
|Merck & Co||331||Unlock company profile|
|Meiji Holdings||176||Unlock company profile|
|Shionogi & Co||139||Unlock company profile|
|Lionco Pharmaceutical Group||131||Unlock company profile|
|Melinta Therapeutics||122||Unlock company profile|
|Mutabilis||120||Unlock company profile|
|Pfizer||113||Unlock company profile|
|Bayer||104||Unlock company profile|
|Innoviva||91||Unlock company profile|
|Insmed||82||Unlock company profile|
|Zoetis||72||Unlock company profile|
|Basilea Pharmaceutica||71||Unlock company profile|
|ContraFect||68||Unlock company profile|
|VenatoRx Pharmaceuticals||67||Unlock company profile|
|Luoxin Pharmacy Group||65||Unlock company profile|
|GSK||54||Unlock company profile|
|Dhanuka Group||54||Unlock company profile|
|AlgiPharma||49||Unlock company profile|
|Novartis||48||Unlock company profile|
|Biogenic Innovations||48||Unlock company profile|
|Hainan Weikang Pharmaceutical (Qianshan)||48||Unlock company profile|
|RedHill Biopharma||46||Unlock company profile|
|Armata Pharmaceuticals||46||Unlock company profile|
|Elanco Animal Health||46||Unlock company profile|
|F. Hoffmann-La Roche||41||Unlock company profile|
|Helperby Therapeutics||37||Unlock company profile|
|Antabio||36||Unlock company profile|
|Summit Therapeutics||36||Unlock company profile|
|Techfields||32||Unlock company profile|
|CSPC Pharmaceutical Group||32||Unlock company profile|
|Venus Remedies||29||Unlock company profile|
|Otonomy||28||Unlock company profile|
|Sarepta Therapeutics||28||Unlock company profile|
|Guangzhou Baiyunshan Pharmaceutical Holdings||25||Unlock company profile|
|Sun Pharmaceutical Industries||25||Unlock company profile|
|Nuance Biotech||25||Unlock company profile|
|Lamellar Biomedical||25||Unlock company profile|
|Advanced Scientific Developements||24||Unlock company profile|
|Fedora Pharmaceuticals||23||Unlock company profile|
|Daiichi Sankyo||23||Unlock company profile|
|Xiangbei Welman Pharmaceutical||22||Unlock company profile|
|Children's Medical Center||22||Unlock company profile|
|Inflammatory Response Research||21||Unlock company profile|
|C. H. Boehringer Sohn||21||Unlock company profile|
|AbbVie||20||Unlock company profile|
|Fosun Holdings||19||Unlock company profile|
|NAEJA-RGM Pharmaceuticals||19||Unlock company profile|
|Qpex Biopharma||18||Unlock company profile|
|Spero Therapeutics||18||Unlock company profile|
Source: GlobalData Patent Analytics
Wockhardt is one of the leading patent filers for anti-bacterial thiazole derivatives. Its product portfolio caters to various therapeutic areas including orthopaedics, dental care, dermatology, rheumatology, gynaecology, paediatrics, cardiology, pain management, nephrology, neurology, and diabetes. The company also concentrates its research in new chemical entities (NCE), generics, abbreviated new drug applications (ANDAs), biosimilars, novel drug delivery systems (NDDS).
In terms of application diversity, Mackay Memorial Hospital is the top company, followed by Theravance Biopharma and Wakunaga Pharmaceutical. By means of geographic reach, Fedora Pharmaceuticals holds the top position, while Lamellar Biomedical and Antabio are in the second and third positions, respectively.
To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Pharmaceutical.